Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
Purpose The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with 18 F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed. Methods...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2016-09, Vol.43 (10), p.1824-1836 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1836 |
|---|---|
| container_issue | 10 |
| container_start_page | 1824 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 43 |
| creator | Christlieb, Sofie Bæk Strandholdt, Casper Nørgaard Olsen, Birgitte Brinkmann Mylam, Karen Juul Larsen, Thomas Stauffer Nielsen, Anne Lerberg Rohde, Max Gerke, Oke Olsen, Karen Ege Møller, Michael Boe Kristensen, Bjarne Winther Abildgaard, Niels Alavi, Abass Høilund-Carlsen, Poul Flemming |
| description | Purpose
The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with
18
F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed.
Methods
Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase.
Results
FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression.
Conclusion
RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression. |
| doi_str_mv | 10.1007/s00259-016-3385-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811882107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811882107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-fccecfbab81370dc28c301360584dfccd9b6bcf45cba74ab643a91f853f77f4b3</originalsourceid><addsrcrecordid>eNqNkU1LxDAQhoMo7rr6A7xIwYuX6kzTJqk3WT9hQQ_rOaRpql3btDbtYf31Zj8UEQRPM8M87zskLyHHCOcIwC8cQJSkISALKRVJyHbIGBmmIQeR7n73HEbkwLkFAIpIpPtkFHGEKGJsTF6uB1UFfVmbsG1K2we313fB0838YjoPlM3X49D26s2sx85Uqjd5YOzHsjYuKG1QLev2VeXGNq3qX0vjLoPWY2VdWtUtvcINVe8OyV6hKmeOtnVCnm9v5tP7cPZ49zC9moU6hqQPC62NLjKVCaQcch0JTQEpg0TEuV_macYyXcSJzhSPVcZiqlIsREILzos4oxNytvFtu-Z9MK6Xdem0qSplTTM4iQJRiAiB_wMFwYBzFB49_YUumqGz_iFrQ6BJmqwMcUPprnGuM4Vsu7L2nyAR5CowuQlM-sDkKjDJvOZk6zxktcm_FV8JeSDaAM6v7Ivpfpz-0_UTdiigBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811035957</pqid></control><display><type>article</type><title>Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Christlieb, Sofie Bæk ; Strandholdt, Casper Nørgaard ; Olsen, Birgitte Brinkmann ; Mylam, Karen Juul ; Larsen, Thomas Stauffer ; Nielsen, Anne Lerberg ; Rohde, Max ; Gerke, Oke ; Olsen, Karen Ege ; Møller, Michael Boe ; Kristensen, Bjarne Winther ; Abildgaard, Niels ; Alavi, Abass ; Høilund-Carlsen, Poul Flemming</creator><creatorcontrib>Christlieb, Sofie Bæk ; Strandholdt, Casper Nørgaard ; Olsen, Birgitte Brinkmann ; Mylam, Karen Juul ; Larsen, Thomas Stauffer ; Nielsen, Anne Lerberg ; Rohde, Max ; Gerke, Oke ; Olsen, Karen Ege ; Møller, Michael Boe ; Kristensen, Bjarne Winther ; Abildgaard, Niels ; Alavi, Abass ; Høilund-Carlsen, Poul Flemming</creatorcontrib><description>Purpose
The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with
18
F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed.
Methods
Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase.
Results
FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression.
Conclusion
RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-016-3385-6</identifier><identifier>PMID: 27102266</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Aged ; Algorithms ; Cardiology ; Diagnosis, Differential ; Enzymes ; Female ; Fluorodeoxyglucose F18 - pharmacokinetics ; Glucose-6-Phosphatase - metabolism ; Hexokinase - metabolism ; Humans ; Image Enhancement - methods ; Image Interpretation, Computer-Assisted - methods ; Imaging ; Lymphatic system ; Lymphoma - diagnostic imaging ; Lymphoma - metabolism ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Middle Aged ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Pilot Projects ; Positron Emission Tomography Computed Tomography - methods ; Radiology ; Reproducibility of Results ; Sensitivity and Specificity ; Tumor Burden ; Young Adult</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2016-09, Vol.43 (10), p.1824-1836</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-fccecfbab81370dc28c301360584dfccd9b6bcf45cba74ab643a91f853f77f4b3</citedby><cites>FETCH-LOGICAL-c405t-fccecfbab81370dc28c301360584dfccd9b6bcf45cba74ab643a91f853f77f4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-016-3385-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-016-3385-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27102266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Christlieb, Sofie Bæk</creatorcontrib><creatorcontrib>Strandholdt, Casper Nørgaard</creatorcontrib><creatorcontrib>Olsen, Birgitte Brinkmann</creatorcontrib><creatorcontrib>Mylam, Karen Juul</creatorcontrib><creatorcontrib>Larsen, Thomas Stauffer</creatorcontrib><creatorcontrib>Nielsen, Anne Lerberg</creatorcontrib><creatorcontrib>Rohde, Max</creatorcontrib><creatorcontrib>Gerke, Oke</creatorcontrib><creatorcontrib>Olsen, Karen Ege</creatorcontrib><creatorcontrib>Møller, Michael Boe</creatorcontrib><creatorcontrib>Kristensen, Bjarne Winther</creatorcontrib><creatorcontrib>Abildgaard, Niels</creatorcontrib><creatorcontrib>Alavi, Abass</creatorcontrib><creatorcontrib>Høilund-Carlsen, Poul Flemming</creatorcontrib><title>Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with
18
F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed.
Methods
Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase.
Results
FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression.
Conclusion
RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Algorithms</subject><subject>Cardiology</subject><subject>Diagnosis, Differential</subject><subject>Enzymes</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Glucose-6-Phosphatase - metabolism</subject><subject>Hexokinase - metabolism</subject><subject>Humans</subject><subject>Image Enhancement - methods</subject><subject>Image Interpretation, Computer-Assisted - methods</subject><subject>Imaging</subject><subject>Lymphatic system</subject><subject>Lymphoma - diagnostic imaging</subject><subject>Lymphoma - metabolism</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pilot Projects</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Radiology</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Tumor Burden</subject><subject>Young Adult</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1LxDAQhoMo7rr6A7xIwYuX6kzTJqk3WT9hQQ_rOaRpql3btDbtYf31Zj8UEQRPM8M87zskLyHHCOcIwC8cQJSkISALKRVJyHbIGBmmIQeR7n73HEbkwLkFAIpIpPtkFHGEKGJsTF6uB1UFfVmbsG1K2we313fB0838YjoPlM3X49D26s2sx85Uqjd5YOzHsjYuKG1QLev2VeXGNq3qX0vjLoPWY2VdWtUtvcINVe8OyV6hKmeOtnVCnm9v5tP7cPZ49zC9moU6hqQPC62NLjKVCaQcch0JTQEpg0TEuV_macYyXcSJzhSPVcZiqlIsREILzos4oxNytvFtu-Z9MK6Xdem0qSplTTM4iQJRiAiB_wMFwYBzFB49_YUumqGz_iFrQ6BJmqwMcUPprnGuM4Vsu7L2nyAR5CowuQlM-sDkKjDJvOZk6zxktcm_FV8JeSDaAM6v7Ivpfpz-0_UTdiigBQ</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Christlieb, Sofie Bæk</creator><creator>Strandholdt, Casper Nørgaard</creator><creator>Olsen, Birgitte Brinkmann</creator><creator>Mylam, Karen Juul</creator><creator>Larsen, Thomas Stauffer</creator><creator>Nielsen, Anne Lerberg</creator><creator>Rohde, Max</creator><creator>Gerke, Oke</creator><creator>Olsen, Karen Ege</creator><creator>Møller, Michael Boe</creator><creator>Kristensen, Bjarne Winther</creator><creator>Abildgaard, Niels</creator><creator>Alavi, Abass</creator><creator>Høilund-Carlsen, Poul Flemming</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20160901</creationdate><title>Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results</title><author>Christlieb, Sofie Bæk ; Strandholdt, Casper Nørgaard ; Olsen, Birgitte Brinkmann ; Mylam, Karen Juul ; Larsen, Thomas Stauffer ; Nielsen, Anne Lerberg ; Rohde, Max ; Gerke, Oke ; Olsen, Karen Ege ; Møller, Michael Boe ; Kristensen, Bjarne Winther ; Abildgaard, Niels ; Alavi, Abass ; Høilund-Carlsen, Poul Flemming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-fccecfbab81370dc28c301360584dfccd9b6bcf45cba74ab643a91f853f77f4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Algorithms</topic><topic>Cardiology</topic><topic>Diagnosis, Differential</topic><topic>Enzymes</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Glucose-6-Phosphatase - metabolism</topic><topic>Hexokinase - metabolism</topic><topic>Humans</topic><topic>Image Enhancement - methods</topic><topic>Image Interpretation, Computer-Assisted - methods</topic><topic>Imaging</topic><topic>Lymphatic system</topic><topic>Lymphoma - diagnostic imaging</topic><topic>Lymphoma - metabolism</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pilot Projects</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Radiology</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Tumor Burden</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christlieb, Sofie Bæk</creatorcontrib><creatorcontrib>Strandholdt, Casper Nørgaard</creatorcontrib><creatorcontrib>Olsen, Birgitte Brinkmann</creatorcontrib><creatorcontrib>Mylam, Karen Juul</creatorcontrib><creatorcontrib>Larsen, Thomas Stauffer</creatorcontrib><creatorcontrib>Nielsen, Anne Lerberg</creatorcontrib><creatorcontrib>Rohde, Max</creatorcontrib><creatorcontrib>Gerke, Oke</creatorcontrib><creatorcontrib>Olsen, Karen Ege</creatorcontrib><creatorcontrib>Møller, Michael Boe</creatorcontrib><creatorcontrib>Kristensen, Bjarne Winther</creatorcontrib><creatorcontrib>Abildgaard, Niels</creatorcontrib><creatorcontrib>Alavi, Abass</creatorcontrib><creatorcontrib>Høilund-Carlsen, Poul Flemming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christlieb, Sofie Bæk</au><au>Strandholdt, Casper Nørgaard</au><au>Olsen, Birgitte Brinkmann</au><au>Mylam, Karen Juul</au><au>Larsen, Thomas Stauffer</au><au>Nielsen, Anne Lerberg</au><au>Rohde, Max</au><au>Gerke, Oke</au><au>Olsen, Karen Ege</au><au>Møller, Michael Boe</au><au>Kristensen, Bjarne Winther</au><au>Abildgaard, Niels</au><au>Alavi, Abass</au><au>Høilund-Carlsen, Poul Flemming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>43</volume><issue>10</issue><spage>1824</spage><epage>1836</epage><pages>1824-1836</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with
18
F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed.
Methods
Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase.
Results
FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression.
Conclusion
RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27102266</pmid><doi>10.1007/s00259-016-3385-6</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2016-09, Vol.43 (10), p.1824-1836 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811882107 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Aged Algorithms Cardiology Diagnosis, Differential Enzymes Female Fluorodeoxyglucose F18 - pharmacokinetics Glucose-6-Phosphatase - metabolism Hexokinase - metabolism Humans Image Enhancement - methods Image Interpretation, Computer-Assisted - methods Imaging Lymphatic system Lymphoma - diagnostic imaging Lymphoma - metabolism Male Medical imaging Medicine Medicine & Public Health Middle Aged Nuclear Medicine Oncology Original Article Orthopedics Pilot Projects Positron Emission Tomography Computed Tomography - methods Radiology Reproducibility of Results Sensitivity and Specificity Tumor Burden Young Adult |
| title | Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A50%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20time-point%20FDG%20PET/CT%20and%20FDG%20uptake%20and%20related%20enzymes%20in%20lymphadenopathies:%20preliminary%20results&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Christlieb,%20Sofie%20B%C3%A6k&rft.date=2016-09-01&rft.volume=43&rft.issue=10&rft.spage=1824&rft.epage=1836&rft.pages=1824-1836&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-016-3385-6&rft_dat=%3Cproquest_cross%3E1811882107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811035957&rft_id=info:pmid/27102266&rfr_iscdi=true |